Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

Cholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers and approximately 3% of gastrointestinal tumors. While rare, the incidence of CAA is on the rise globally. Often asymptomatic at early stages, CCA is usually diagnosed at advanced stage with a dismal prognosis and limited therapeutic options. The 5-year survival rate of patients with advanced metastatic disease is only 2%. There is therefore an urgent need to develop more effective therapies to improve clinical outcomes in this patient population.

source https://medicalxpress.com/news/2022-11-team-large-cholangiocarcinoma-preclinical-drug.html